Insider · CIK 0001635065
Barbara-Jean Anne Bormann-Kennedy
Files at XERS (Xeris Biopharma Holdings, Inc.). First filing Dec 15, 2025, latest Jun 5, 2026.
In brief
Barbara-Jean Anne Bormann-Kennedy files SEC Form 4 as director at XERS (Xeris Biopharma Holdings, Inc.). Since Dec 15, 2025, Barbara-Jean Anne Bormann-Kennedy has reported 0 open-market buys worth $0 and 2 open-market sells worth $204k, the latest filed on Jun 5, 2026.
A track record needs three past buys with six months of prices behind them; Barbara-Jean Anne Bormann-Kennedy has 0, so none is measured yet.
The newest scored trade: sold $98k of XERS on Jun 4, 2026, filed Jun 5, 2026, scored 25 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $204k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
XERS: Xeris Biopharma Holdings, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Xeris Biopharma Holdings, Inc. | $98k 16,000 shares | -11% | +41% from low-38% from high | |
| 20Weak | Xeris Biopharma Holdings, Inc. | $106k 15,000 shares | -10% | +124% from low-28% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 4, 2026 | XERS XERIS BIOPHARMA HOLDINGS, INC. | 16,000 0.01% of outstanding | $94k | Jun 4, 2026 | none |
| Dec 12, 2025 | XERS XERIS BIOPHARMA HOLDINGS, INC. | 15,000 0.01% of outstanding | $105k | Dec 12, 2025 | none |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 4, 2026 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -16,000 | $6.09 | $98k | 126,500 | Jun 5, 2026 |
| Jun 4, 2026 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock10b5-1 | +24,193 | $0.00 | $0 | 150,693 | Jun 5, 2026 |
| Jun 4, 2026 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +32,996 | $6.15 | $203k | 32,996 | Jun 5, 2026 |
| Dec 12, 2025 | XERS Xeris Biopharma Holdings, Inc. | SOpen-market sale Common Stock10b5-1 | -15,000 | $7.09 | $106k | 142,500 | Dec 15, 2025 |
| Jun 4, 2025 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 157,500 | Jun 4, 2025 |
| Jun 5, 2024 | XERS Xeris Biopharma Holdings, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 107,500 | Jun 5, 2024 |
Questions about Barbara-Jean Anne Bormann-Kennedy
Answered from the filings on this page, as of the latest one.
Is Barbara-Jean Anne Bormann-Kennedy buying or selling?
In the last 12 months Barbara-Jean Anne Bormann-Kennedy reported 0 open-market buys worth $0 and 2 open-market sells worth $204k on SEC Form 4; the latest was sold $98k of XERS on Jun 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Barbara-Jean Anne Bormann-Kennedy's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Barbara-Jean Anne Bormann-Kennedy has 0.
Where does Barbara-Jean Anne Bormann-Kennedy file Form 4?
Barbara-Jean Anne Bormann-Kennedy has filed Form 4 at XERS (Xeris Biopharma Holdings, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.